Mentor to study botulinum toxin to treat head, neck spasms

By Elaine Rigoli

Tampa, Fla., May 15 - Mentor Corp. has started the phase 1 study of its botulinum toxin type A product, focused on the therapeutic indication of the treatment of pain associated with adult onset spasmodic torticollis/cervical dystonia in the United States.

Adult onset spasmodic torticollis/cervical dystonia is a syndrome that causes abnormal involuntary movements or posture of the head and neck, often followed by pain in the back portions of the neck, according to a news release.

"The initiation of the U.S. clinical program for torticollis is another significant milestone for Mentor and our botulinum toxin product-development program. We are aggressively advancing our product-development pipeline and will leverage our opportunities broadly to maximize shareholder value," president and chief executive officer Joshua H. Levine said in the release.

Santa Barbara, Calif.-based Mentor develops science-based products for the aesthetics and urologic specialties markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.